SBIR/STTR Research Award

Development of a5 nicotinic receptor agonists for smoking cessation

Award identifier f557e0813450dd53bb3688f4323a329b7454b026d7e1b537b2ac12299ca8187bAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$793,191

Program and phase

SBIR · Phase II

Award year

2015

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
OPHIDION, INC.
Proposal award date
2015-05-01
Contract end date
2018-04-30
UEI
NNGSPLRM7DL6
Solicitation number
PA14-071
Topic code
R44

Research abstract

DESCRIPTION provided by applicant Nicotine is a serious health problem that is resistant to treatment for millions of people In the United States tobacco use is responsible for about deaths per year and an estimated of these tobacco related deaths are the result of secondhand smoke exposure Cigarette smoking costs more than $ billion i e $ billion in lost productivity plus $ billion in health care expenditures Nicotine is one of the most heavily used addictive drugs and accounts for of lung cancer cases in the U S Nicotine the addictive component of tobacco binds to specialized proteins in the brain called a nicotinic receptors Evidence suggests that a receptors can be a contributing factor in the risk towards smoking dependence indicating its potential as a therapeutic development strategy for smoking cessation Common strategies for smoking cessation therapies are to break the reward cycle between smoking and the reward pleasure signal that is the typical consequence of nicotine consumption a receptors are located in a brain region that mediates aversion to nicotine the medial habenula Activation of the medial habenula can cause reduction of nicotine intake in animal models This proposal focuses on the development of a drug that activates a receptors to help smokers quit smoking The research performed under this award will transform early stage candidate molecules into drug like pre clinical leads A successful project outcome will be the development of a clinical candidate that can be tested in humans with the end goal of delivering a smoking cessation drug to the public PUBLIC HEALTH RELEVANCE This proposal focuses on the development of a drug to help addicted smokers quit smoking Tobacco use is responsible for about deaths per year in the US and an estimated of these tobacco related deaths are the result of secondhand smoke exposure Nicotine related diseases place a heavy burden on the health care industry and have a substantial health and societal impact

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

4 SBIR/STTR records share this UEI (2008–2015). Reported award amounts total $2,245,584. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.